New drug combo shows promise for Hard-to-Treat breast cancer

NCT ID NCT04920708

First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This phase 2 study tests whether adding the experimental drug ipatasertib to standard hormone therapy and a targeted drug can help people with a specific type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. The study includes 57 participants whose cancer did not respond well to initial treatment. Researchers use a blood test to track cancer DNA and guide treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Imperial College University Hospitals NHS Trust

    London, W2 1NY, United Kingdom

  • Mount Vernon Cancer Centre

    London, Surrey, HA6 2RN, United Kingdom

  • Nottingham City Hospital

    Nottingham, United Kingdom

  • Oxford University Hospitals

    Oxford, OX3 7LE, United Kingdom

  • Royal Cornwall Hospital

    Truro, Cornwall, TR1 3LQ, United Kingdom

  • Royal Free Hospital

    London, NW3 2QC, United Kingdom

  • Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • University College London Hospital

    London, United Kingdom

  • Velindre Cancer Centre

    Cardiff, Wales, CF14 2TL, United Kingdom

  • Western General Hospital

    Edinburgh, EH4 2XU, United Kingdom

Conditions

Explore the condition pages connected to this study.